Personal innovative approach in radiation therapy of lung cancer- functional lung avoidance SPECT-guided (ASPECT) radiation therapy: a study protocol for phase II randomised double-blind clinical trial

Azza Ahmed Khalil, Eric Hau, Val Gebski, Cai Grau, Harriet Gee, Tine Bisballe Nyeng, Katrina West, Stine Kramer, David Farlow, Marianne Knap, Ditte Sloth Møller, Lone Hoffmann, Katherina P Farr, Azza Ahmed Khalil, Eric Hau, Val Gebski, Cai Grau, Harriet Gee, Tine Bisballe Nyeng, Katrina West, Stine Kramer, David Farlow, Marianne Knap, Ditte Sloth Møller, Lone Hoffmann, Katherina P Farr

Abstract

Background: Radiation therapy (RT) plays a key role in curative-intent treatment for locally advanced lung cancer. Radiation induced pulmonary toxicity can be significant for some patients and becomes a limiting factor for radiation dose, suitability for treatment, as well as post treatment quality of life and suitability for the newly introduced adjuvant immunotherapy. Modern RT techniques aim to minimise the radiation dose to the lungs, without accounting for regional distribution of lung function. Many lung cancer patients have significant regional differences in pulmonary function due to smoking and chronic lung co-morbidity. Even though reduction of dose to functional lung has shown to be feasible, the method of preferential functional lung avoidance has not been investigated in a randomised clinical trial.

Methods: In this study, single photon emission computed tomography (SPECT/CT) imaging technique is used for functional lung definition, in conjunction with advanced radiation dose delivery method in randomised, double-blind trial. The study aims to assess the impact of functional lung avoidance technique on pulmonary toxicity and quality of life in patients receiving chemo-RT for lung cancer. Eligibility criteria are biopsy verified lung cancer, scheduled to receive (chemo)-RT with curative intent. Every patient will undergo a pre-treatment perfusion SPECT/CT to identify functional lung. At radiation dose planning, two plans will be produced for all patients on trial. Standard reference plan, without the use of SPECT imaging data, and functional avoidance plan, will be optimised to reduce the dose to functional lung within the predefined constraints. Both plans will be clinically approved. Patients will then be randomised in a 2:1 ratio to be treated according to either the functional avoidance or the standard plan. This study aims to accrue a total of 200 patients within 3 years. The primary endpoint is symptomatic radiation-induced lung toxicity, measured serially 1-12 months after RT. Secondary endpoints include: a quality of life and patient reported lung symptoms assessment, overall survival, progression-free survival, and loco-regional disease control.

Discussion: ASPECT trial will investigate functional avoidance method of radiation delivery in clinical practice, and will establish toxicity outcomes for patients with lung cancer undergoing curative chemo-RT.

Trial registration: Clinicaltrials.gov Identifier: NCT04676828 . Registered 1 December 2020.

Keywords: Functional imaging; Lung cancer; Perfusion SPECT/CT; Radiation therapy; Radiation-induced lung toxicity.

Conflict of interest statement

EH Advisory panel, honoria and research funding from Astra Zeneca.

KF member of the editorial board for BMC Cancer.

© 2021. The Author(s).

Figures

Fig. 1
Fig. 1
ASPECT study design

References

    1. The Danish Oncology Lung Cancer Group. The 2017 Annual Rapport. .
    1. Marks LB, Bentzen SM, Deasy JO, Kong FM(S), Bradley JD, Vogelius IS, el Naqa I, Hubbs JL, Lebesque JV, Timmerman RD, Martel MK, Jackson A. Radiation dose-volume effects in the lung. Int J Radiat Oncol Biol Phys. 2010;76(3):S70–S76. doi: 10.1016/j.ijrobp.2009.06.091.
    1. Voong KR, Naidoo J. Radiation pneumonitis after definitive chemoradiation and durvalumab for non-small cell lung cancer. Lung Cancer. 2020;146:23–29. doi: 10.1016/j.lungcan.2020.05.035.
    1. Farr KP, Khalil AA, Knap MM, Møller DS, Grau C. Development of radiation pneumopathy and generalised radiological changes after radiotherapy are independent negative prognostic factors for survival in non-small cell lung cancer patients. Radiother Oncol. 2013;107(3):382–388. doi: 10.1016/j.radonc.2013.04.024.
    1. Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, Kurata T, Chiappori A, Lee KH, de Wit M, Cho BC, Bourhaba M, Quantin X, Tokito T, Mekhail T, Planchard D, Kim YC, Karapetis CS, Hiret S, Ostoros G, Kubota K, Gray JE, Paz-Ares L, de Castro Carpeño J, Faivre-Finn C, Reck M, Vansteenkiste J, Spigel DR, Wadsworth C, Melillo G, Taboada M, Dennis PA, Özgüroğlu M. Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC. N Engl J Med. 2018;379(24):2342–2350. doi: 10.1056/NEJMoa1809697.
    1. Farr KP, Kramer S, Khalil AA, Morsing A, Grau C. Role of perfusion SPECT in prediction and measurement of pulmonary complications after radiotherapy for lung cancer. Eur J Nucl Med Mol Imaging. 2015;42(8):1315–1324. doi: 10.1007/s00259-015-3052-3.
    1. Mortensen J, Gutte H. SPECT/CT and pulmonary embolism. Eur J Nucl Med Mol Imaging. 2014;41(Suppl 1):S81–S90. doi: 10.1007/s00259-013-2614-5.
    1. Bucknell NW, Hardcastle N, Bressel M, Hofman MS, Kron T, Ball D, Siva S. Functional lung imaging in radiation therapy for lung cancer: a systemic review and meta-analysis. Radiother Oncol. 2018;129(2):196–208. doi: 10.1016/j.radonc.2018.07.014.
    1. Farr KP, Kallehauge JF, Møller D, et al. Inclusion of functional information from perfusion SPECT improves predictive value of dose-volume parameters in lung toxicity. Radiother Oncol. 2015;117(1):9–16. doi: 10.1016/j.radonc.2015.08.005.
    1. Christian JA, Partridge M, Nioutsikou E, Cook G, McNair HA, Cronin B, Courbon F, Bedford JL, Brada M. The incorporation of SPECT functional lung imaging into inverse radiotherapy planning for non-small cell lung cancer. Radiother Oncol. 2005;77(3):271–277. doi: 10.1016/j.radonc.2005.08.008.
    1. Hardcastle N, Hofman MS, Hicks RJ, Callahan J, Kron T, MacManus MP, Ball DL, Jackson P, Siva S. Accuracy and utility of deformable image registration in (68) Ga 4D PET/CT assessment of pulmonary perfusion changes during and after lung radiation therapy. Int J Radiat Oncol Biol Phys. 2015;93(1):196–204. doi: 10.1016/j.ijrobp.2015.05.011.
    1. Farr KP, West K, Yeghiaian-Alvandi R, Stensmyr R, Farlow D, Chicco A, Hau E. Functional perfusion image guided radiation treatment planning for locally advanced lung cancer. Phys Radiat Oncol. 2019;11:76–81. doi: 10.1016/j.phro.2019.08.007.
    1. Bailey DL, Willowson KP. An evidence-based review of quantitative SPECT imaging and potential clinical applications. J Nucl Med. 2013;54(1):83–89. doi: 10.2967/jnumed.112.111476.
    1. Rankine LJ, Wang Z, Bier E, Kelsey CR, Marks LB, Driehuys B, Das SK. Pulmonary gas exchange-guided functional avoidance treatment planning for thoracic radiation therapy using hyperpolarized 129Xe magnetic resonance imaging. Int J Radiat Oncol Biol Phys. 2020;108(3):S102–S103. doi: 10.1016/j.ijrobp.2020.07.2281.
    1. Hoover D, et al. Functional lung avoidance for individualized radiotherapy (FLAIR): study protocol for a randomized, double-blind clinical trial. BMC Cancer. 2014;14(1):934. doi: 10.1186/1471-2407-14-934.
    1. Osborne DR, Jaszczak R, Coleman RE. Single photon emission computed tomography and its application in the lung. Radiol Clin N Am. 1983;21(4):789–800.
    1. Robbins ME, Brunso-Bechtold JK, Peiffer AM, Tsien CI, Bailey JE, Marks LB. Imaging radiation-induced normal tissue injury. Radiat Res. 2012;177(4):449–466. doi: 10.1667/RR2530.1.
    1. McGuire SM, Marks LB, Yin FF, Das SK. A methodology for selecting the beam arrangement to reduce the intensity-modulated radiation therapy (IMRT) dose to the SPECT-defined functioning lung. Phys Med Biol. 2010;55(2):403–416. doi: 10.1088/0031-9155/55/2/005.
    1. Seppenwoolde Y, Muller SH, Theuws JCM, Baas P, Belderbos JSA, Boersma LJ, Lebesque JV. Radiation dose-effect relations and local recovery in perfusion for patients with non small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2000;47(3):681–690. doi: 10.1016/S0360-3016(00)00454-5.
    1. Siva S, Thomas R, Callahan J, Hardcastle N, et al. High-resolution pulmonary ventilation and perfusion PET/CT allows for functionally adapted intensity modulated radiotherapy in lung cancer. Radiother Oncol. 2015;115:157–162. doi: 10.1016/j.radonc.2015.04.013.
    1. Scheenstra AEH, Rossi MMG, Belderbos JSA, Damen EMF, Lebesque JV, Sonke JJ. Local dose–effect relations for lung perfusion post stereotactic body radiotherapy. Radiother Oncol. 2013;107(3):398–402. doi: 10.1016/j.radonc.2013.04.003.
    1. Junan Z, Ma J, Zhou S, Hubbs JL, et al. Radiation-induced reductions in regional lung perfusion: 0.1-12 year data from a prospective clinical study. Int J Radiat Oncol Biol Phys. 2010;1:425–432.
    1. Farr KP, Moller DS, Khalil AA, Kramer S, Morsing A, Grau C. Loss of lung function after chemo-radiotherapy for NSCLC measured by perfusion SPECT/CT: correlation with radiation dose and clinical morbidity. Acta Oncol. 2015;54(9):1350–1354. doi: 10.3109/0284186X.2015.1061695.
    1. Liss A, Marsh RB, Kapadia NS, McShan DL, et al. Decreased lung perfusion after breast/Chest Wall irradiation: quantitative results from a prospective clinical trial. Int J Radiat Oncol Biol Phys. 2017;97(2):296–302. doi: 10.1016/j.ijrobp.2016.10.012.

Source: PubMed

Sponsorit ja yhteistyökumppanit

Sairaudet

Huumeiden interventiot

3
Tilaa